Premium
Identification of transcription factors associated with castration‐resistance: Is the serum responsive factor a potential therapeutic target?
Author(s) -
Prencipe Maria,
Madden Stephen F.,
O'Neill Amanda,
O'Hurley Gillian,
Culhane Aedin,
O'Connor Darran,
Klocker Helmut,
Kay Elaine W.,
Gallagher William M.,
Watson William R.
Publication year - 2013
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.22618
Subject(s) - castration , transcription factor , medicine , bioinformatics , biology , hormone , genetics , gene
BACKGROUND Advanced prostate cancer is treated by hormone ablation therapy. However, despite an initial response, the majority of men relapse to develop castration‐resistant disease for which there are no effective treatments. We have previously shown that manipulating individual proteins has only minor alterations on the resistant phenotype so we hypothesize that targeting the central transcription factors (TFs) would represent a better therapeutic approach. METHODS We have undertaken a transcriptomic analysis of gene expression differences between the androgen‐dependent LNCaP parental cells and its castration‐resistant Abl and Hof sublines, revealing 1,660 genes associated with castration‐resistance. Using effective bioinformatic techniques, these transcriptomic data were integrated with TF binding sites resulting in a list of TFs associated with the differential gene expression observed. RESULTS Following validation of the gene‐chip results, the serum response factor (SRF) was chosen for clinical validation and functional analysis due to its recent association with prostate cancer progression. SRF immunoreactivity in prostate tumor samples was shown for the first time to be associated with castration‐resistance. SRF inhibition by siRNA and the small molecule inhibitor CCG‐1423 resulted in decreased proliferation. CONCLUSION SRF is a key TF by which resistant cells survive with depleted levels of androgens representing a target for therapeutic manipulation. Prostate 73: 743–753, 2013. © 2013 Wiley Periodicals, Inc.